Adverse event reporting every six months "unwarranted" for OTCs -- NDMA.
This article was originally published in The Tan Sheet
Executive Summary
ADVERSE EVENT REPORTING EVERY SIX MONTHS IS "UNWARRANTED" FOR OTCs and other drugs with a long marketing history, the Non-prescription Drug Manufacturers Association stated in Jan. 25 comments to FDA. In response to a recent agency proposal revising the schedule for periodic adverse reaction reports for marketed drugs, NDMA said it supports the proposed reporting schedule for new chemical entities. "However, for drugs with a long marketing history (including OTC drugs)," NDMA said, "this proposed change is thought to be unwarranted and burdensome."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning